Preliminary Study of Correlation Between Androgen or Stathmin Expression in Patients with Triple Negative Breast Cancer and Its Clinicopathologic Factors_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HE Yu ^1,2 , LUO Jing ¹ ,  ZHOU Leilei ¹

1.Department of Breast Surgery， Sichuan Provincial People’s Hospital， Chengdu 610072， Sichuan Province， China;;
2.The Second Department of Surgery， People’s Hospital of Luzhou City， Luzhou 646100， Sichuan Province， China;

Corresponding author：

ZHOU Leilei, Email: zhouleilei2006d@126.com

Keywords：

Triple negative breast cancer; Androgen receptor; Stathmin; Immunohistochemistry; Clinicopa-thologic factor

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the expressions of androgen （AR） and Stathmin in triple negative breast cancer （TNBC） and analyze the correlation between these expressions and clinicopathologic features.
Methods 　Eighty-three patients who were diagnosed as TNBC and met the inclusion criteria from 2005 to 2009 in the Sichuan Provincial People’s Hospital were collected retrospectively. The expressions of AR and Stathmin in the TNBC tissues by using the method of EnVision immunohistochemistry. The correlation between AR or Stathmin expression and age， tumor size， lymph node status， or histological grade was analyzed by Spearman test.
Results 　The AR and Stathmin positive expression rates in the patients with TNBC were 37.3% （31/83） and 98.8% （82/83）， respectively. The AR expression was positively correlated with age（rs=0.302， P=0.006）and pathological grade （rs=0.225， P=0.041）， but was not correlated with tumor size or lymph node status. The Stathmin expression was not correlated with age， tumor size， lymph node status， or pathological grade （P＞0.05） .
Conclusions 　The AR expression is correlated with the age or pathological grade but Stathmin expression was all not correlated with the clinicopathologic features. AR or Stathmin as a prognosis indicator in patients with TNBC are needed to more research.

Citation： HE Yu,LUO Jing,ZHOU Leilei. Preliminary Study of Correlation Between Androgen or Stathmin Expression in Patients with Triple Negative Breast Cancer and Its Clinicopathologic Factors. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(8): 846-850. doi: Copy

1.	Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
2.	Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
3.	Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
4.	Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
5.	Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
6.	Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
7.	Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
8.	Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
9.	Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
10.	Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
11.	Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
12.	Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
13.	Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
14.	Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
15.	Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
16.	Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
17.	Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
18.	Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
19.	Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
20.	Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
21.	Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
22.	Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
23.	Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
24.	Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
25.	Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
26.	Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
27.	Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
28.	Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
29.	Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
30.	-551.
31.	-1787.

1. Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
2. Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
3. Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
4. Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
5. Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
6. Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
7. Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
8. Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
9. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
10. Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
11. Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
12. Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
13. Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
14. Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
15. Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
16. Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
17. Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
18. Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
19. Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
20. Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
21. Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
22. Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
23. Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
24. Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
25. Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
26. Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
27. Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
28. Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
29. Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
30. -551.
31. -1787.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Preliminary Study of Correlation Between Androgen or Stathmin Expression in Patients with Triple Negative Breast Cancer and Its Clinicopathologic Factors

Abstract Full text Figures/Tables Video References Cited by

Format

Content